Atomoxetine and Duloxetine: Evaluation of a Potential Pharmacokinetic Drug-Drug Interaction

Open access

Abstract

Objective: The present research aimed to investigate whether a pharmacokinetic drug interaction exists between atomoxetine, a substrate of CYP2D6 and duloxetine, an enzymatic inhibitor of the same metabolic pathway.

Methods: Twenty-three healthy volunteers were enrolled in an open-label, non-randomized, sequential, 2-period clinical study. During the trial, they received a single dose of atomoxetine 25 mg (Period 1:Reference) followed by a combination of atomoxetine 25 mg and duloxetine 30 mg, after a pretreatment regimen with duloxetine 30-60 mg/day for 4 days (Period 2:Test). The pharmacokinetic parameters of atomoxetine and its main metabolite (4-hydroxyatomoxetine-O-glucuronide) were estimated using a non-compartmental approach and statistical tests were used to compare these parameters between study periods.

Results: A total of 22 subjects, extensive metabolizers (EMs), were considered for the final report of the study findings. Duloxetine influenced the plasma concentration-time profile of both parent drug and its glucuronidated metabolite. The pharmacokinetic and statistical analysis revealed that pretreatment with the enzymatic inhibitor increased the mean atomoxetine AUC0–t (from 1151.19±686.52 to 1495.54±812.40 [ng*h/mL]) and AUC0–∞ (from 1229.15±751.04 to 1619.37±955.01 [ng*h/mL]) while kel was decreased and the mean t1/2 was prolonged. With regard to 4-hydroxyatomoxetine-O-glucuronide, Cmax was reduced from 688.76±270.27 to 621.60±248.82 [ng/mL] after coadministration of atomoxetine and duloxetine.

Conclusions: Duloxetine had an impact on the pharmacokinetics of atomoxetine as it increased the exposure to the latter by ~30%. Although the magnitude of this pharmacokinetic interaction is rather small, a potential clinical relevance cannot be ruled out with certainty without further investigation.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Corman SL Fedutes BA Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391–9.

  • 2. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9.

  • 3. Sauer J-M Ring BJ Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–90.

  • 4. Ring BJ Gillespie JS Eckstein JA Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002 ;30(3):319–23.

  • 5. Yu G Li G-F Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26(4):314-26.

  • 6. Knadler MP Lobo E Chappell J Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281–94.

  • 7. Wernicke JF Gahimer J Yalcin I Wulster-radcliffe M Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf. 2005;4(6):987-93.

  • 8. Carter NJ McCormack PL. Duloxetine: A review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523–41.

  • 9. Sobanski E Paslakis G Schredl M et al. Managing ADHD in adults with common comorbidities. In: Surman C ed. ADHD in adults. A practical guide to evaluation and managament. Current Clinical Psychiatry. Totowa NJ: Humana Press; 2013. p. 137–54.

  • 10. Bond DJ Hadjipavlou G Lam RW et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24(1):23–37.

  • 11. Kooij JJS Bijlenga D Salerno L et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14–34.

  • 12. Dodangi N Habibi N Astaneh AN. Preliminary investigation on duloxetine efficacy in the treatment of children with attention-deficit hyperactivity disorder. J Compr Pediatr. 2015; 6(4):e27482. doi: 10.17795/compreped-27482.

  • 13. Niederhofer H. Duloxetine may improve some symptoms of attention-deficit/hyperactivity disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2): PCC.09l00807. doi: 10.4088/PCC.09l00807pin.

  • 14. Faul F Erdfelder E Lang AG Buchner A. G*Power 3: A flexible statistical power analysis program for the social behavioral and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.

  • 15. Todor I Popa A Neag M et al. Evaluation of the potential pharmacokinetic interaction between atomoxetine and fluvoxamine in healthy volunteers. Pharmacology. 2017;99(1-2):84-88.

  • 16. Todor I Popa A Neag M et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci. 2016;19(2):198–207.

  • 17. Todor I Popa A Neag M et al. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. Clujul Med. 2015;88(4):513-520.

  • 18. Thapar A Cooper M. Attention deficit hyperactivity disorder. Lancet.2015;387(10024):1240–50.

  • 19. Biederman J Petty CR Evans M Small J Faraone S V. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.

  • 20. Faraone S V Biederman J Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.

  • 21. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–9.

  • 22. Fayyad J De Graaf R Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.

  • 23. Wang B Yang L-P Zhang XZ Huang SQ Bartlam M Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573–643.

  • 24. Lin ND Norman H Regev A et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015; 15:134. doi: 10.1186/s12876-015-0373-4.

  • 25. Belle DJ Ernest CS Sauer J Smith BP Thomasson HR Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219-27.

  • 26. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2015; 12:27-39.

  • 27. Fredriksen M Halmøy A Faraone S V Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD : A review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-27.

  • 28. Hennissen L Bakker MJ Banaschewski T et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD : a systematic review and meta-analysis of trials of methylphenidate amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199–215.

  • 29. Kasi PM Mounzer R Gleeson GH. Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep Med. 2011;2011:952584. doi: 10.1155/2011/952584.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 6 6 4
PDF Downloads 15 15 9